Dmitriy Zamarin

Has grant

Professor

Icahn School of Medicine at Mount Sinai

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Dmitriy Zamarin is a Professor at the Icahn School of Medicine at Mount Sinai in the United States. His research primarily focuses on cancer immunotherapy, particularly in endometrial cancer and the immune response to tumors. Recent articles by Dr. Zamarin investigate topics such as personalized vaccination strategies, the molecular landscape of cancer, and innovative approaches to enhance therapeutic efficacy in patients.

Recent Grants

Grant: Close

Defining immunotherapy targets in bladder cancer microenvironment using oncolytic viruses

Open Date: 2014-07-15

Close Date: 2016-07-14

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (3)

Xiaoxiao Ma

Assistant Professor

The University of Alabama at Birmingham School of Medicine

UNITED STATES

View details

Daniel Morton

University of Oklahoma Health Sciences Center

UNITED STATES

View details

Christina Henson

Assistant Professor, Program Director

University of Oklahoma Health Sciences Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Dmitriy Zamarin

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Cancer trials as opportunities to serve and learn from individuals with human immunodeficiency virus

Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study

High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer

Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype

Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission

Shedding Light on PARP Inhibitor Response through Functional Imaging

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

Author Correction: Fundamental immune–oncogenicity trade-offs define driver mutation fitness (Nature, (2022), 606, 7912, (172-179), 10.1038/s41586-022-04696-z)

Beyond T Cells: IgA Incites Immune Recognition in Endometrial Cancer

Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity

Collaborators (3)

Xiaoxiao Ma

Daniel Morton

Christina Henson

Make your next move.